{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:44Z","timestamp":1786120364539,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/nrl.0b013e31823968d3","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T03:43:34Z","timestamp":1320119014000},"page":"S43-S46","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of Parkinson Disease, Time and Dosage"],"prefix":"10.1097","volume":"17","author":[{"given":"\u00c1ngel","family":"Sesar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mat\u00edas","family":"Arbelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier L\u00f3pez","family":"del Val","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210211","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinsons disease who were treated with ropinirole or levodopa. 056 Study Group.","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"R2-9-20210211","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","article-title":"Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"R3-9-20210211","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","article-title":"Slower progression of Parkinsons disease with ropinirole versus levodopa: the REAL-PET study.","volume":"54","author":"Whone","year":"2003","journal-title":"Ann Neurol"},{"key":"R4-9-20210211","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","article-title":"A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.","volume":"61","year":"2004","journal-title":"Arch Neurol"},{"key":"R6-9-20210211","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","article-title":"Stages in the development of Parkinsons disease-related pathology.","volume":"318","author":"Braak","year":"2004","journal-title":"Cell Tissue Res"},{"issue":"Suppl 4","key":"R9-9-20210211","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1353-8020(09)70842-9","article-title":"Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies.","volume":"15","author":"Onofrj","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"R10-9-20210211","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/11204570-000000000-00000","article-title":"Pramipexole extended release: in Parkinsons disease.","volume":"24","author":"Chwieduk","year":"2010","journal-title":"CNS Drugs"},{"issue":"Suppl 4","key":"R11-9-20210211","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S1353-8020(09)70843-0","article-title":"Transdermal delivery of dopamine receptor agonists.","volume":"15","author":"Reichmann","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 4","key":"R12-9-20210211","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S1353-8020(09)70844-2","article-title":"Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinsons disease.","volume":"15","author":"Antonini","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 3","key":"R13-9-20210211","doi-asserted-by":"crossref","first-page":"S560","DOI":"10.1002\/mds.22020","article-title":"Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.","volume":"23","author":"Grace","year":"2008","journal-title":"Mov Disord"},{"key":"R14-9-20210211","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneur.61.10.1563","article-title":"Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.","volume":"61","author":"Olanow","year":"2004","journal-title":"Arch Neurol"},{"key":"R17-9-20210211","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2377-7-20","article-title":"Effect of educational intervention on medication timing in Parkinsons disease: a randomized controlled trial.","volume":"7","author":"Grosset","year":"2007","journal-title":"BMC Neurol"},{"key":"R19-9-20210211","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/mds.21831","article-title":"Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinsons disease.","volume":"23","author":"Kulkarni","year":"2008","journal-title":"Mov Disord"},{"key":"R20-9-20210211","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/mds.20602","article-title":"Suboptimal medication adherence in Parkinsons disease.","volume":"20","author":"Grosset","year":"2005","journal-title":"Mov Disord"},{"key":"R21-9-20210211","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/mds.22999","article-title":"Prevalence and cost of medication nonadherence in Parkinsons disease: evidence from administrative claims data.","volume":"25","author":"Davis","year":"2010","journal-title":"Mov Disord"},{"issue":"Suppl 4","key":"R22-9-20210211","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S1353-8020(09)70847-8","article-title":"Impulse control disorders in Parkinsons disease: definition, epidemiology, risk factors, neurobiology and management.","volume":"15","author":"Ceravolo","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"R23-9-20210211","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/mds.22112","article-title":"Adherence to antiparkinson medication in a multicenter European study.","volume":"24","author":"Grosset","year":"2009","journal-title":"Mov Disord"},{"key":"R24-9-20210211","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/jnnp.2005.064709","article-title":"Measuring therapy adherence in Parkinsons disease: a comparison of methods.","volume":"77","author":"Grosset","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R25-9-20210211","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication.","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"R26-9-20210211","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance.","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"}],"container-title":["The Neurologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00127893-201111001-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:32:26Z","timestamp":1786048346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00127893-201111001-00009"}},"subtitle":["\u201cDoes Simple Dosage Facilitate Compliance and Therapeutic Goals?\u201d"],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1097\/nrl.0b013e31823968d3","relation":{},"ISSN":["1074-7931"],"issn-type":[{"value":"1074-7931","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}